Literature DB >> 1281303

Platelet activation leads to increased c-src kinase activity and association of c-src with an 85-kDa tyrosine phosphoprotein.

S Wong1, A B Reynolds, J Papkoff.   

Abstract

We have used platelets as a model system to study the function of c-src in signal transduction and cell adhesion. Numerous proteins were found to be phosphorylated on tyrosine in response to thrombin-induced platelet activation and aggregation. Two phases of phosphorylation were observed, with the second phase, but not the first, being inhibited by blocking platelet aggregation with an Arg-Gly-Asp-Ser tetrapeptide. As a first step towards identifying those proteins phosphorylated on tyrosine and to determine the specific role of p60src during platelet activation, we looked for changes in p60src kinase activity and for associations of p60src with other tyrosine phosphoproteins. The data presented here demonstrate an increase in p60src kinase activity within 1 min of thrombin-induced activation. Furthermore, p60src transiently associates with a tyrosine phosphoprotein during platelet activation and aggregation. This tyrosine phosphoprotein, p80/85, is a previously characterized cytoskeletal substrate for v-src in transformed cells. The data presented here suggest a model in which p60src functions in platelets to link upstream events, such as cell-surface adhesive interactions, with changes in platelet shape and cytoskeletal organization.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1281303

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  p42 mitogen-activated protein kinase and p90 ribosomal S6 kinase are selectively phosphorylated and activated during thrombin-induced platelet activation and aggregation.

Authors:  J Papkoff; R H Chen; J Blenis; J Forsman
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

2.  Thrombopoietin stimulates cortactin translocation to the cytoskeleton independently of tyrosine phosphorylation.

Authors:  I Lopez; V Duprez; J Melle; F Dreyfus; S Lévy-Tolédano; M Fontenay-Roupie
Journal:  Biochem J       Date:  2001-06-15       Impact factor: 3.857

3.  Suppression of c-Src activity by C-terminal Src kinase involves the c-Src SH2 and SH3 domains: analysis with Saccharomyces cerevisiae.

Authors:  S M Murphy; M Bergman; D O Morgan
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

4.  Identification of a novel cortactin SH3 domain-binding protein and its localization to growth cones of cultured neurons.

Authors:  Y Du; S A Weed; W C Xiong; T D Marshall; J T Parsons
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

5.  Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets.

Authors:  B Klages; U Brandt; M I Simon; G Schultz; S Offermanns
Journal:  J Cell Biol       Date:  1999-02-22       Impact factor: 10.539

6.  The actin binding proteins cortactin and HS1 are dispensable for platelet actin nodule and megakaryocyte podosome formation.

Authors:  Steven G Thomas; Natalie S Poulter; Danai Bem; Brenda Finney; Laura M Machesky; Stephen P Watson
Journal:  Platelets       Date:  2016-10-25       Impact factor: 3.862

7.  Invasion of epithelial cells by Shigella flexneri induces tyrosine phosphorylation of cortactin by a pp60c-src-mediated signalling pathway.

Authors:  C Dehio; M C Prévost; P J Sansonetti
Journal:  EMBO J       Date:  1995-06-01       Impact factor: 11.598

8.  Interferon alpha inhibits a Src-mediated pathway necessary for Shigella-induced cytoskeletal rearrangements in epithelial cells.

Authors:  G Duménil; J C Olivo; S Pellegrini; M Fellous; P J Sansonetti; G T Nhieu
Journal:  J Cell Biol       Date:  1998-11-16       Impact factor: 10.539

9.  Cortactin, an 80/85-kilodalton pp60src substrate, is a filamentous actin-binding protein enriched in the cell cortex.

Authors:  H Wu; J T Parsons
Journal:  J Cell Biol       Date:  1993-03       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.